Sino Biopharmaceut (OTCMKTS:SBMFF) – Investment analysts at Jefferies Group issued their FY2017 earnings per share (EPS) estimates for shares of Sino Biopharmaceut in a research report issued to clients and investors on Sunday. Jefferies Group analyst E. Huang expects that the company will earn $0.05 per share for the year. Jefferies Group also issued estimates for Sino Biopharmaceut’s FY2018 earnings at $0.06 EPS and FY2019 earnings at $0.07 EPS.
Separately, Zacks Investment Research cut Sino Biopharmaceut from a “buy” rating to a “hold” rating in a research note on Tuesday, October 10th.
ILLEGAL ACTIVITY WARNING: This piece of content was originally published by Community Financial News and is the sole property of of Community Financial News. If you are reading this piece of content on another website, it was stolen and republished in violation of United States and international copyright and trademark law. The legal version of this piece of content can be accessed at https://www.com-unik.info/2017/12/13/research-analysts-offer-predictions-for-sino-biopharmaceuts-fy2017-earnings-sbmff.html.
About Sino Biopharmaceut
Sino Biopharmaceutical Limited, researches, develops, manufactures, and markets Chinese medicines and chemical medicines in Hong Kong. The company operates through three segments: Modernized Chinese Medicines and Chemical Medicines, Investment, and Others. Its principal products include hepatitis medicines, such as Tianqingganmei injections, Runzhong dispersible tablets, Mingzheng capsules, Tianqingganping enteric capsules, and Ganlixin injections and capsules; and cardio-cerebral medicines comprising Yilunping and Tuotuo tablets, as well as Tianqingning injections; and oncology medicines consisting of Zhiruo, Saiweijian, and Tianqingyitai injections.
Receive News & Ratings for Sino Biopharmaceut Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sino Biopharmaceut and related companies with MarketBeat.com's FREE daily email newsletter.